commercialize methods of increasing epithelial cell growth. Please contact John D. Hewes, PhD at 301–435–3121 or *hewesj@mail.nih.gov* for more information.

Dated: October 20, 2008.

Richard U. Rodriguez,

Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.

[FR Doc. E8–25566 Filed 10–24–08; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Eye Institute; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Eye Institute Special Emphasis Panel; K08, K23, K99–NEI Research Training Applications.

Date: November 14, 2008.

Time: 8:30 a.m. to 5 p.m.

Agenda: To review and evaluate grant applications.

Place: Doubletree Hotel and Executive Meeting Center, 8120 Wisconsin Avenue, Bethesda, MD 20814.

Contact Person: Samuel Rawlings, PhD, Chief, Scientific Review Branch, Division of Extramural Research National Eye Institute, 5635 Fishers Lane, Suite 1300, MSC 9300, Bethesda, MD 20892–9300, 301–451–2020, *rawlings@nei.nih.gov*.

Name of Committee: National Eye Institute Special Emphasis Panel; NEI Cooperative Agreement Review.

Date: November 20, 2008.

Time: 3 p.m. to 5:30 p.m.

Agenda: To review and evaluate cooperative agreement Applications.

Place: National Institutes of Health, 5635 Fishers Lane, Bethesda, MD 20892, (Telephone Conference Call).

Contact Person: Houmam H Araj, PhD, Scientific Review Administrator, Division of Extramural Research, National Eye Institute, NIH, 5635 Fishers Lane, Suite 1300, Bethesda, MD 20892–9602, 301–451–2020, *ha50c@nih.gov*.

Name of Committee: National Eye Institute Special Emphasis Panel; NEI Core Grants for Vision Research Review.

Date: December 5, 2008.

Time: 8:30 a.m. to 5 p.m.

Agenda: To review and evaluate grant applications.

Place: Embassy Suites at the Chevy Chase Pavilion, 4300 Military Road, NW., Washington, DC 20015.

Contact Person: Houmam H Araj, PhD, Scientific Review Administrator, Division of Extramural Research, National Eye Institute, NIH, 5635 Fishers Lane, Suite 1300, Bethesda, MD 20892–9602, 301–451–2020, *ha50c@nih.gov*.

(Catalogue of Federal Domestic Assistance Program Nos. 93.867, Vision Research, National Institutes of Health, HHS)

Dated: October 17, 2008.

Jennifer Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. E8–25357 Filed 10–24–08; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Neurological Disorders and Stroke; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Neurological Disorders and Stroke Special Emphasis Panel; Resident Research RFA.

Date: December 8–9, 2008.

Time: 8 a.m. to 6 p.m.

Agenda: To review and evaluate grant applications.

Place: The Fairmont Washington, DC, 2401 M Street, NW., Washington, DC 20037.

Contact Person: Raul A Saavedra, PhD, Scientific Review Administrator, Scientific Review Branch, Division of Extramural Research, NINDS/NIH/DHHS, Nsc; 6001 Executive Blvd., Ste. 3208, Bethesda, MD 20892–9529, 301–496–9223, *saavedrr@ninds.nih.gov.*

(Catalogue of Federal Domestic Assistance Program Nos. 93.853, Clinical Research Related to Neurological Disorders; 93.854, Biological Basis Research in the Neurosciences, National Institutes of Health, HHS)

Dated: October 15, 2008.

Jennifer Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. E8–25626 Filed 10–24–08; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Notice of Meeting: Secretary's Advisory Committee on Genetics, Health, and Society

Pursuant to Public Law 92–463, notice is hereby given of the 17th meeting of the Secretary's Advisory Committee on Genetics, Health, and Society (SACGHS), U.S. Public Health Service. The meeting will be held from 8 a.m. to approximately 5:30 p.m. on Monday, December 1, 2008, and 8 a.m. to approximately 3 p.m. on Tuesday, December 2, 2008, at the Hubert H. Humphrey Building, 200 Independence Avenue, SW., Washington, DC 20201. The meeting will be open to the public with attendance limited to space available. The meeting also will be Web cast.

For most of the first day of the meeting, SACGHS will review a preliminary draft report that addresses questions about whether gene patents and certain licensing practices are affecting patient access to genetic tests. SACGHS will discuss the draft report and determine whether it is ready to be released for public comment. Later in the day, the Committee will hear presentations about diagnostic laboratory standards and technology platforms and the role they are playing in innovation of genetic technologies. On day two, the Committee will continue to discuss priority issues and future study topics and come to a final decision about its strategic study plan.

As always, the Committee welcomes hearing from anyone wishing to provide public comment on any issue related to genetics, health and society. Individuals who would like to provide public comment should notify the SACGHS Executive Secretary, Ms. Sarah Carr, by telephone at 301–496–9838 or e-mail at *carrs@od.nih.gov*. The SACGHS office is located at 6705 Rockledge Drive, Suite 750, Bethesda, MD 20892. Anyone planning to attend the meeting who is in need of special assistance, such as sign language interpretation or other

reasonable accommodations, is also asked to contact the Executive Secretary.

Under authority of 42 U.S.C. 217a, Section 222 of the Public Health Service Act, as amended, the Department of Health and Human Services established SACGHS to serve as a public forum for deliberations on the broad range of human health and societal issues raised by the development and use of genetic and genomic technologies and, as warranted, to provide advice on these issues. The draft meeting agenda and other information about SACGHS, including information about access to the Web cast, will be available at the following Web site: *http://www4.od.nih.gov/oba/sacghs.htm.*

Dated: October 20, 2008.

Jennifer Spaeth,

Director, NIH Office of Federal Advisory Committee Policy.

[FR Doc. E8–25485 Filed 10–24–08; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HOMELAND SECURITY

[Docket No. DHS–2006–0073]

National Protection and Programs Directorate; Notice of Availability of Risk-Based Performance Standards Guidance for the Chemical Facility Anti-Terrorism Standards

AGENCY: National Protection and Programs Directorate, DHS.

ACTION: Notice of availability; request for comments.

SUMMARY: The Department of Homeland Security (DHS) is accepting comments on the draft ''Risk-Based Performance Standards'' Guidance associated with the Chemical Facility Anti-Terrorism Standards.

DATES: Comments must be received by November 26, 2008.

ADDRESSES: Comments must be identified by docket number DHS–2006–0073 and may be submitted by one of the following methods:

- *Federal Rulemaking Portal: http://www.regulations.gov.* Follow the instructions for submitting comments.
- *Mail:* Dennis Deziel, U.S. Department of Homeland Security, National Protection and Programs Directorate, Office of Infrastructure Protection, Infrastructure Security Compliance Division, Mail Stop 8100, Washington, DC 20528.

FOR FURTHER INFORMATION CONTACT: Dennis Deziel, Office of Infrastructure Protection, Mail Stop 8100, Washington, DC 20528, telephone number (703) 235–5263.

SUPPLEMENTARY INFORMATION:

I. Public Participation

DHS invites interested persons to contribute suggestions and comments on the draft document entitled ''Risk-Based Performance Standards Guidance'' (RBPS Guidance) by submitting written data, views, or arguments. Comments that will provide the most assistance to DHS will explain the reason for any recommended changes to the RBPS Guidance and include data, information, or authority that supports such recommended changes. DHS requests that commenters identify the proposed changes by page and line number, and/or by Figure or Table number. The RBPS Guidance can be viewed or downloaded at *http://www.dhs.gov/chemicalsecurity* and *http://www.regulations.gov.*

Instructions: All submissions received must include the agency name and docket number for this action. All comments received will be posted without change to *http://www.regulations.gov,* including any personal information provided. You may submit your comments and material by one of the methods specified in the **ADDRESSES** section above. Please submit your comments and any supporting material by only one means to avoid the receipt and review of duplicate submissions. If you submit comments by mail, your submission should be an unbound document and no larger than 8.5 by 11 inches to enable copying and electronic document management.

Docket: The RBPS Guidance and any comments received can be viewed at *http://www.regulations.gov* by searching the docket number referenced above.

II. Background

In Section 550 of the Homeland Security Appropriations Act of 2007 (Pub. L. 109–295) (Section 550), Congress gave DHS regulatory authority over security at high-risk chemical facilities. Section 550 instructed DHS to require all high-risk chemical facilities to complete Security Vulnerability Assessments (SVAs), develop Site Security Plans (SSPs), and implement protective measures necessary to meet DHS-defined risk-based performance standards.

Pursuant to its congressional mandate, DHS promulgated the Chemical Facility Anti-Terrorism Standards (CFATS), 6 CFR Part 27, the interim final regulations setting forth the requirements that high risk (i.e., ''covered'') chemical facilities must meet to comply with the Act. *See* 72 FR 17688 (Apr. 9, 2007). Among other things, CFATS establishes eighteen Risk-Based Performance Standards (RBPSs), which identify the areas for which DHS will examine a high-risk facility's security posture; they include perimeter security, access control, personnel surety, and cyber security.

To meet the RBPSs, covered facilities may choose whatever security programs or processes they deem appropriate, so long as DHS determines that those measures achieve the requisite level of performance in each applicable area. The programs and processes a high-risk facility ultimately chooses to implement to meet these standards must be described in the facility's SSP or, if the facility chooses, in an Alternative Security Program (ASP) that meets the requirements of Section 550 and CFATS. It is through a review of the SSP (or ASP), combined with an on-site inspection, that DHS will determine whether or not a high-risk facility has met the requisite levels of performance established by the RBPSs, given the facility's individual circumstances.

As required by 6 CFR 27.230(a), DHS has developed the RBPS Guidance to assist high-risk chemical facilities in selecting and implementing appropriate protective measures and practices to meet the applicable RBPSs. The draft RBPS Guidance describes the general level of performance that facilities in each of the risk-based tiers created by CFATS should strive to achieve under each RBPS. It also seeks to help facilities comply with CFATS by describing in greater detail the eighteen RBPSs enumerated in CFATS, and by providing examples of various security measures and practices that facilities could consider to achieve the desired level of performance for each RBPS at each tier.

The draft RBPS Guidance reflects DHS's current views on certain aspects of the RBPSs and does not have the force or effect of law. The specific security measures and practices discussed in this document are neither mandatory nor necessarily the ''preferred solution'' for complying with the RBPSs. Rather, they are examples of measures and practices that a high risk facility may choose to consider as part of its overall strategy to address the RBPSs. High-risk facility owners/operators have the option to choose and implement other measures to meet the RBPSs based on the facility's circumstances, including its tier level, security issues and risks, physical and operating environments, and other appropriate factors, so long as DHS determines that the suite of measures